- Home
- FIGS vs SYRE Comparison
FIGS vs SYRE Comparison
Compare FIGS & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- SYRE
- Stock Information
- Founded
- FIGS 2013
- SYRE 2013
- Country
- FIGS United States
- SYRE United States
- Employees
- FIGS N/A
- SYRE N/A
- Industry
- FIGS Apparel
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- SYRE Health Care
- Exchange
- FIGS Nasdaq
- SYRE Nasdaq
- Market Cap
- FIGS 1.1B
- SYRE 1.1B
- IPO Year
- FIGS 2021
- SYRE 2016
- Fundamental
- Price
- FIGS $6.98
- SYRE $16.23
- Analyst Decision
- FIGS Sell
- SYRE Strong Buy
- Analyst Count
- FIGS 4
- SYRE 6
- Target Price
- FIGS $5.38
- SYRE $57.60
- AVG Volume (30 Days)
- FIGS 2.0M
- SYRE 681.2K
- Earning Date
- FIGS 11-06-2025
- SYRE 11-06-2025
- Dividend Yield
- FIGS N/A
- SYRE N/A
- EPS Growth
- FIGS N/A
- SYRE N/A
- EPS
- FIGS 0.04
- SYRE N/A
- Revenue
- FIGS $569,581,000.00
- SYRE N/A
- Revenue This Year
- FIGS $4.63
- SYRE N/A
- Revenue Next Year
- FIGS $3.69
- SYRE N/A
- P/E Ratio
- FIGS $160.76
- SYRE N/A
- Revenue Growth
- FIGS 3.41
- SYRE N/A
- 52 Week Low
- FIGS $3.57
- SYRE $10.91
- 52 Week High
- FIGS $7.54
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- FIGS 51.93
- SYRE 52.04
- Support Level
- FIGS $6.50
- SYRE $15.87
- Resistance Level
- FIGS $7.38
- SYRE $17.18
- Average True Range (ATR)
- FIGS 0.25
- SYRE 0.88
- MACD
- FIGS 0.00
- SYRE 0.08
- Stochastic Oscillator
- FIGS 49.49
- SYRE 70.65
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.